ticker stringlengths 2 5 | disease stringlengths 3 196 | stage stringclasses 15
values | date stringlengths 19 19 | catalyst stringlengths 18 760 | label int64 -1 1 |
|---|---|---|---|---|---|
SGEN | HER2+ Metastatic Breast Cancer (MBC) | Approved | 2020-04-17 00:00:00 | FDA Approval announced April 17, 2020. | 1 |
PFE | Ulcerative colitis | Approved | 2023-10-13 00:00:00 | FDA Approved on October 13, 2023. | 1 |
MBIO | B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL) | Phase 1/2 | 2023-08-16 00:00:00 | Initial Phase 1/2 data reported clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy, noted August 16, 2023. | 1 |
ACHL | Non-Small Cell Lung Cancer (NSCLC) | Phase 1/2 | 2022-12-06 00:00:00 | Phase 1/2a data reported 1 partial response (PR), and 6 stable disease with overall durable clinical benefit at 12 weeks in 71% of evaluable patients, noted December 6, 2022. | 1 |
SNDX | Relapsed/refractory (R/R) acute leukemias | Phase 2 | 2023-10-02 00:00:00 | Phase 2 trial met its primary endpoint at the protocol-defined interim analysis stage with a complete remission (CR) or a CR with partial hematological recovery (CRh) rate of 23% among the 57 efficacy evaluable patients in the pooled KMT2Ar acute leukemia cohort, noted October 2, 2023. | 1 |
SXTP | COVID-19 patients with mild-moderate symptoms and low risk of disease progression | Phase 1a | 2023-09-18 00:00:00 | IND withdrawn, noted September 18, 2023 | 0 |
RLAY | Cholangiocarcinoma (CCA) | Phase 1 | 2023-10-12 00:00:00 | Phase 1 data from non-CCA expansion cohort presented at AACR-NCI-EORTC reported a 35% overall response rate (ORR), and nine of 26 patients experienced a partial response (PR), noted October 12, 2023. | 1 |
MRK | Head and neck squamous cell carcinoma (HNSCC) | Approved | 2019-06-11 00:00:00 | FDA Approval announced June 11, 2019. | 1 |
RHHBY | Wet age-related macular degeneration (nAMD) and diabetic macular edema (DME) | Approved | 2022-01-31 00:00:00 | Approved January 31, 2022. | 1 |
BIVI | Ascites | Phase 2b | 2023-03-13 00:00:00 | Phase 2b data reported that treatment resulted in a 34% reduction in ascites fluid during the 28 days after treatment initiation compared to the 28 days prior to treatment, noted March 13, 2023. | 1 |
AVDL | Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia | Approved | 2014-06-30 00:00:00 | Approved June 30, 2014. | 1 |
ANAB | Generalized pustular psoriasis | Phase 3 | 2023-10-09 00:00:00 | Phase 3 top-line data met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile, noted October 9, 2023. | 1 |
HOTH | Atopic Dermatitis (AD) | Phase 1b | 2023-09-06 00:00:00 | Phase 1b final results reported that 78% of patients reported that their overall health had improved since starting BioLexa as compared to 22% stating that there was no change in their health, or their health was worse, noted September 6, 2023. | 1 |
PFE | Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) | Phase 3 | 2021-03-03 00:00:00 | FDA approval announced March 3 2021. | 1 |
BPTS | COVID-19 | Phase 2/3 | 2023-05-25 00:00:00 | Phase 2/3 data reported that at 28 days the adjusted difference in the proportion of patients with hospital discharge of 11% showed a trend towards a statistically significant difference in BIO101 group versus placebo in ITT population, noted May 25, 2023. | 1 |
SNY | COVID-19 vaccine | Phase 3 | 2021-12-15 00:00:00 | Phase 3 data reported that the vaccine is well tolerated, with a safety profile similar to currently approved COVID-19 vaccines, noted December 15, 2021. | 1 |
TAK | Dengue Vaccine | Phase 3 | 2022-06-09 00:00:00 | Phase 3 data reported that treatment prevented 84% of hospitalizations and 61% of symptomatic dengue illness overall, with identified safety risks, noted June 9, 2022. | 1 |
RXDX | Ulcerative colitis | Phase 2 | 2023-03-01 00:00:00 | Phase 2 trial met all ranked secondary endpoints, noted March 1, 2023. | 0 |
LLY | Treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC) | Approved | 2022-09-21 00:00:00 | FDA Approval on September 21, 2022. | 1 |
NAVB | Lymphatic-tissue tracing agent | Approved | 2013-03-13 00:00:00 | Approved March 13, 2013. | 1 |
CNTX | ER+, HER2-, ESR1-mutated Breast Cancer | Approved | 2023-01-31 00:00:00 | Approved January 31, 2023. | 1 |
APTO | Acute myeloid leukemia (AML) | Phase 1/2 | 2023-10-30 00:00:00 | Phase 1/2 data demonstrated 44% ORR with TUS/VEN in Difficult-to-Treat VEN Failure R/R AML Patients, noted October 30, 2023. | 1 |
GSK | Severe eosinophilic asthma - pediatric | Approved | 2019-06-06 00:00:00 | FDA Approval announced June 6, 2019. | 1 |
COYA | Alzheimer’s Disease (AD) | Phase 2 | 2023-10-09 00:00:00 | Phase 2 enrollment completed, noted October 9, 2023. | 0 |
CMPS | Treatment Resistant Depression (TRD) | Phase 2b | 2023-05-26 00:00:00 | Phase 2b more than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological support, noted May 26, 2023. | 1 |
SNY | Cystic fibrosis | Phase 1/2 | 2021-03-17 00:00:00 | Phase 1/2 interim analysis March 17, 2021. Safe and well tolerated with no serious adverse events but no increase in lung function (ppFEV1) evident. | 1 |
PLX | Fabry disease | Approved | 2023-05-10 00:00:00 | Approved May 10, 2023. | 1 |
SNY | Sickle Cell Disease | Phase 1/2 | 2021-12-13 00:00:00 | Phase 1/2 data reported that total hemoglobin stabilized by Week 26 after treatment in all four patients. Fetal hemoglobin level increased from 0.1-11% at screening to 14-39% in all four patients and was 38% in the longest-treated patient at 91 weeks, noted December 13, 2021. | 1 |
KRYS | Epidermolysis Bullosa | Approved | 2023-05-19 00:00:00 | Approved May 19, 2023. | 1 |
MRK | Ovarian Cancer | Phase 1/2 | 2022-06-06 00:00:00 | Results from Phase 1 and Phase 2 expansion cohort presented at ASCO reported that G3/G2 immune-related AE and injection site reactions were observed in 1/1 and 1/3 pts treated at DL1, and in 1/0 and 2/2 pts at DL2, respectively. At Phase 1, one patient with MSI-High clear cell subtype had an ongoing CR after 26 months ... | 1 |
IONS | Cardiovascular (CV) risk reduction and hypertriglyceridemia | Phase 2b | 2021-11-24 00:00:00 | Phase 2b updated data demonstrated that in the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo, noted November 24, 2021. | 1 |
BGNE | Gastric/gastroesophageal junction adenocarcinoma (G/GEJC) | Phase 1/2 | 2023-10-20 00:00:00 | Phase 1b/2 data presented at ESMO reported that the confirmed objective response rate by investigator (INV) was 75.8% and median progression-free survival was 16.7 months, noted October 20, 2023. | 1 |
ABBV | Neurogenic Detrusor Overactivity | Approved | 2021-02-10 00:00:00 | FDA approval announced February 10, 2021. | 1 |
CPIX | Pain and fever in patients three months to six months of age | Approved | 2023-05-15 00:00:00 | Expanded label approval by FDA on May 15, 2023. | 1 |
SNDX | Chronic Graft versus host disease (cGvHD) | Phase 2 | 2023-07-24 00:00:00 | Phase 2 trial results met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks, noted July 24, 2023. | 0 |
RDHL | H. pylori | Approved | 2023-09-18 00:00:00 | https://www.biopharmcatalyst.com/company/RDHL/news/159168 | 0 |
ACIU | Alzheimer’s disease (AD) | Phase 2 | 2021-06-02 00:00:00 | Phase 2 interim analysis June 2, 2021. Good safety confirmed. | 0 |
PRAX | Early-seizure-onset SCN2A developmental and epileptic encephalopathy (DEE) | Phase 3 | 2023-10-02 00:00:00 | Phase 3 results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients, noted October 2, 2023. | 1 |
IONS | Spinal muscular atrophy (SMA) | Approved | 2016-12-23 00:00:00 | Approved December 23, 2016. | 1 |
FATE | B-cell Leukemias and Lymphomas | Phase 1 | 2022-12-10 00:00:00 | Phase 1 interim data reported that 1 of 2 patients naïve to CAR T-cell therapy achieved an objective response (1 CR) at Day 30, and 2 of 6 patients previously treated with CAR T-cell therapy achieved an objective response (1 CR, 1 PR) at Day 30, noted December 12, 2022. | 1 |
AZN | COVID-19 | Phase 3 | 2023-01-26 00:00:00 | FDA no longer allows treatment to be used as Emergency Use Authorization (EUA) due to the lack of effectiveness against the currently circulating variants, noted January 26, 2023. | 1 |
INDV | Opioid Overdose | Approved | 2023-05-23 00:00:00 | Approved May 22, 2023. | 1 |
GLUE | MYC-driven solid tumors | Phase 1/2 | 2023-10-17 00:00:00 | Phase 1/2 initial data study demonstrated favorable tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in heavily pre-treated patients with lung and high-grade neuroendocrine cancers., noted October 17, 2023 | 1 |
ZVRA | Urea cycle disorder (UCD) | Approved | 2022-12-23 00:00:00 | Approved December 23, 2022. | 1 |
RHHBY | Ulcerative colitis | Phase 2b | 2023-06-22 00:00:00 | Additional Phase 2b data continue to support RVT-3101's potential as a first-in-class anti-TL1A antibody, demonstrating sustained efficacy across a broad dose range measured at 56 weeks, noted June 22, 2023 | 1 |
IPSEY | Glabellar and lateral canthal lines | CRL | 2023-10-03 00:00:00 | CRL received October 3, 2023. | 0 |
LGND | Pneumococcal disease | Approved | 2021-07-16 00:00:00 | FDA approval announced July 16, 2021. | 1 |
AMGN | Neuromyelitis Optica Spectrum Disorder | Approved | 2020-06-11 00:00:00 | FDA Approval announced June 11, 2020. | 1 |
PFE | Gastric cancer | Phase 3 | 2017-11-28 00:00:00 | Phase 3 data released November 28, 2017 - primary endpoint not met. | 0 |
REGN | Ebola | Approved | 2020-10-14 00:00:00 | FDA Approval announced October 14, 2020. | 1 |
PRVB | Ulcerative Colitis | Phase 1b | 2019-05-08 00:00:00 | Phase 1b top-line data May 8, 2019 noted primary safety and tolerability endpoint met but secondary efficacy endpoints were not met. | 1 |
APTX | Post-traumatic stress disorder (PTSD) | Phase 2 | 2020-10-19 00:00:00 | Phase 2 data released October 19, 2020. Primary endpoint met. | 0 |
BMY | Melanoma | Phase 3 | 2022-03-14 00:00:00 | Phase 3 data did not meet the primary endpoints, noted March 14, 2022. | 1 |
INCY | Anemia and Post-essential Thrombocythemia Myelofibrosis | Phase 1/2 | 2022-12-12 00:00:00 | Phase 1/2 data reported predominantly grade 1/2 TEAEs and no dose-limiting toxicities (DLTs), noted December 12, 2022. | 0 |
NVAX | COVID-19 vaccine | Approved | 2022-07-13 00:00:00 | Emergency Use Authorization (EUA) granted July 13, 2022. | 0 |
CLSD | Wet age-related macular degeneration | Phase 1/2 | 2023-10-16 00:00:00 | Phase 1/2a results demonstrated the key benefits targeting the site of disease at the back of the eye, noted October 16, 2023. | 1 |
GMAB | Metastatic cervical cancer | Phase 1/2 | 2022-06-06 00:00:00 | Phase 1b/2 data reported an 41% objective response rate, noted June 6, 2022. | 0 |
RCKT | Leukocyte Adhesion Deficiency-I (LAD-I) | Phase 1/2 | 2022-05-19 00:00:00 | Phase 2 top-line data reported a 100% survival rate at 12-months post-infusion, with statistically significant reduction in the rate of all-cause hospitalizations and severe infections, noted May 19, 2022. | 1 |
CALA | Non-small cell lung cancer (NSCLC) patients with genetic mutation NRF2/KEAP1 | Phase 2 | 2021-11-05 00:00:00 | Phase 2 interim analysis demonstrated lack of clinical benefit among patients treated. Trial termination, noted November 5, 2021. | 1 |
AKBA | ARDS in subjects with COVID-19 and hypoxemia | Phase 2 | 2022-08-04 00:00:00 | Phase 2 trial data reported that at Day 14, the proportions of subjects who had a 6, 7 or 8 on the NIAID-OS were 13.3% for vadadustat versus 16.9% for placebo, missing its primary endpoint, noted August 4, 2022. | 0 |
IMVT | Myasthenia Gravis (MG) | Phase 2 | 2020-08-25 00:00:00 | Phase 2 data released August 25, 2020. | 0 |
INCY | Steroid-refractory chronic GVHD (Graft versus host disease) | Approved | 2021-09-22 00:00:00 | Approved September 22, 2021. | 1 |
SWTX | Multiple Myeloma | Phase 1/2 | 2023-06-09 00:00:00 | Phase 1/2 data presented at EHA Data from 34 patients with low-dose and 37 patients with monotherapy are presented. Patients had a median (range) age of 68 (48–81) years and a median (range) of 5 (3–14) prior lines of therapy. As of the data cutoff (Dec 9, 2022), patients received a median (range) of 4 (1–20) cycles of... | 1 |
IMMP | Ulcerative Colitis | Phase 2 | 2021-01-21 00:00:00 | Phase 2 trial discontinued following interim analysis - January 21, 2021. | -1 |
DRRX | Schizophrenia | Approved | 2018-07-27 00:00:00 | FDA Approval announced July 27, 2018. | 1 |
MRK | Crohn’s Disease | Phase 2a | 2023-03-03 00:00:00 | Phase 2a primary and secondary results reported efficacy in biologic-experienced subjects consistent with overall population and consistent across subgroups and irrespective of presence of ADA, noted March 3, 2023. | 0 |
LLY | COVID-19 | Phase 3 | 2021-04-08 00:00:00 | Phase 3 trial did not meet primary endpoint - April 8, 2021. | 1 |
MYOV | Endometriosis | Phase 3 | 2022-07-28 00:00:00 | Phase 3 data reported that trials met both co-primary endpoints with 75% of women in the relugolix combination therapy group in both studies achieving a clinically meaningful reduction in dysmenorrhea compared with 27% and 30% of women in the placebo groups at Week 24, respectively, noted July 28, 2022. | 1 |
PRTA | AL Amyloidosis | Phase 3 | 2022-12-12 00:00:00 | Phase 3 VITAL data reported a significant improvement in time to all-cause mortality, noted December 12, 2022. | 1 |
BHC | Ocular Inflammation | Approved | 2019-02-25 00:00:00 | FDA approval announced February 25, 2019. | 1 |
PFE | Endometriosis | Phase 3 | 2022-07-28 00:00:00 | Phase 3 data reported that trials met both co-primary endpoints with 75% of women in the relugolix combination therapy group in both studies achieving a clinically meaningful reduction in dysmenorrhea compared with 27% and 30% of women in the placebo groups at Week 24, respectively, noted July 28, 2022. | 1 |
AZN | Type-2 diabetes | Approved | 2017-02-28 00:00:00 | Approval announced February 28, 2017. | 1 |
LSTA | Solid Tumors | Phase 2a | 2023-09-12 00:00:00 | Phase 2a dosing initiated on head and neck squamous cell carcinoma cohort, noted Septemeber 12, 2023. | 0 |
OMER | Cataract surgery | Approved | 2014-06-02 00:00:00 | Approved June 2, 2014. | 1 |
KROS | Myelodysplastic syndromes (MDS) | Phase 2 | 2023-11-02 00:00:00 | Phase 2 data from ASH abstract reported that the median treatment duration was 166 days (range 6 to 649). Most participants (89.8%) had at least 1 treatment-emergent adverse event (TEAE), and 32.2% had TEAEs considered treatment-related, noted November 2, 2023. | 1 |
ORTX | MPS-IIIA | Phase 1/2 | 2023-05-19 00:00:00 | Initial data shared at ASGCT reported that four out of five patients continued to gain cognitive skills in line with development in healthy children, noted May 20, 2023. | 0 |
AZN | Hyperkalaemia | Approved | 2018-05-18 00:00:00 | Approval announced May 18, 2018. | 1 |
RDHL | Crohn’s disease | Phase 3 | 2018-07-30 00:00:00 | Phase 3 data released July 30, 2018. Primary endpoint met but further trial required. | 0 |
AMGN | Relapsed Multiple Myeloma | Approved | 2018-01-17 00:00:00 | sNDA approved January 17, 2018. | 1 |
CGTX | Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (AMD) | Phase 1 | 2023-07-11 00:00:00 | Phase 2 trial dosing initiated, noted July 11, 2023. | 0 |
AYTU | Attention deficit hyperactivity disorder (ADHD) | Approved | 2017-09-15 00:00:00 | Approval announced September 15, 2017. | 1 |
ADPT | Newly Diagnosed Multiple Myeloma | Phase 2a | 2022-12-10 00:00:00 | Cohort 2a efficacy and safety data presented at ASH demonstrated complete and durable responses in a significant proportion of patients, noted on December 10, 2022. | 1 |
NTLA | Transthyretin amyloidosis (ATTR) | Phase 1 | 2023-11-02 00:00:00 | Phase 1 updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of follow-up, noted November 2, 2023. | 1 |
SNY | COVID-19 vaccine | Phase 1/2 | 2021-09-28 00:00:00 | Phase 1/2 interim data noted neutralizing antibody seroconversion in 91% to 100% of study participants. No safety concern has been observed, noted September 28, 2021. | 1 |
GRTS | COVID-19 booster (60+) | Phase 1 | 2023-10-11 00:00:00 | Additional Phase 1 data reported at IDweek noted that durable binding and high neutralizing antibodies were induced and sustained for up to at least 12 months, noted October 11, 2023. | 0 |
AADI | Soft Tissue Sarcoma | Phase 1 | 2023-06-05 00:00:00 | Phase 1 data at ASCO reported that 3 of the 18 evaluable patients having achieved a partial response, and 13 achieving stable disease, noted June 5, 2023. | 1 |
INCY | COVID-19 | Approved | 2022-05-11 00:00:00 | FDA approval on May 11, 2022. | 1 |
BIIB | Small Fiber Neuropathy | Phase 2 | 2021-09-16 00:00:00 | Phase 2 200mg dosing data met primary endpoint, did not meet statistical significance for secondary endpoints. Phase 2 330 mg dosing data did not meet the primary endpoint or secondary endpoints, September 16, 2021. | 1 |
IMMP | Metastatic breast cancer (MBC) | Phase 2b | 2022-05-04 00:00:00 | Phase 2b biomarker data reported a statistically significant increase in innate and adaptive immune response biomarkers and six patient subgroups with improvements in Overall Survival (OS), noted May 4, 2022. | 1 |
SVRA | Heart failure with preserved ejection fraction (HFpEF) | Phase 2 | 2018-03-11 00:00:00 | Phase 2 top line data presented March 11, 2018 failed to meet primary endpoint. | 1 |
MRK | Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Approved | 2018-06-13 00:00:00 | Approval announced June 13, 2018. | 1 |
NVO | Type 2 diabetes | Phase 3 | 2022-06-03 00:00:00 | Phase 3a trial met primary endpoint, noted June 3, 2022. | 0 |
ZLDPF | Short bowel syndrome (SBS) | Phase 3 | 2022-09-30 00:00:00 | Phase 3 trial results reported that trial met its primary endpoint, noted September 30, 2022. | 0 |
TVTX | Focal segmental glomerulosclerosis (FSGS) | Phase 3 | 2023-11-03 00:00:00 | Phase 3 presentations at ASN showed that sparsentan delivered a clinically meaningful benefit at 108 weeks with significant proteinuria reduction, higher rates of partial and complete remission, and lower rates of end-stage kidney disease, noted November 3, 2023. | 1 |
PFE | Ulcerative colitis | Approved | 2018-05-30 00:00:00 | Approval announced May 30, 2018. | 1 |
PCRX | Post surgical pain | Approved | 2018-04-06 00:00:00 | Approval announced April 6, 2018. | 1 |
INCY | Rheumatoid arthritis | Approved | 2018-06-01 00:00:00 | FDA approval announced for low dose only - June 1, 2018. | 1 |
AVIR | COVID-19 | Phase 2 | 2023-04-25 00:00:00 | Fast Track Designation granted on April 25, 2023. | 0 |
MRK | HER2 amplified metastatic colorectal cancer | Approved | 2023-01-19 00:00:00 | Approved January 19, 2023. | 1 |
SYRS | Acute myeloid leukemia (AML) | Phase 2 | 2022-12-10 00:00:00 | Phase 2 data reported a 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression, noted December 10, 2022. | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.